Ivax highlights Paxene safety compared to Taxol at advisory committee review for AIDS-related KS.
IVAX HIGHLIGHTS PAXENE SAFETY PROFILE COMPARED TO TAXOL at the Sept. 19 Oncologic Drugs Advisory Committee meeting review of Paxene for treatment of AIDS-related Kaposi's sarcoma. While Paxene's "tumor response rate is similar to that of Taxol when used at the same dose and schedule," Paxene's "safety is no worse, and in certain adverse events, may be better than that of Taxol," Baker Norton Medical Director Gregory Harriman asserted.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth